Orexigen’s chief executive elected to PhRMA Board
pharmafile | April 23, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | PhRMA, orexigen
Biopharma firm Orexigen has announced that its president and chief executive Michael Narachi has been elected to the Board of directors at PhRMA.
Narachi will serve as a director for a term of two years at Pharmaceutical Research and Manufacturers of America, which represents US biopharma research and biotech companies.
Narachi said: “I’m honoured to join the board of PhRMA, and I’m looking forward to being a part of an organisation whose mission is to conduct effective advocacy for public policies that encourage discovery of important new medicines for patients.”
PhRMA president and chief executive John Castellani added: “I am pleased to welcome a respected industry leader, Mike Narachi, to PhRMA’s Board of directors. Mike’s many years of experience in the biopharmaceutical sector make him an invaluable addition to our Board as we continue to fight for public policies that recognise the true value of innovative medicines for both patients and the American economy.”
Narachi has served as Orexigen’s president and chief executive and a member of Orexigen’s board of directors since March 2009.
Before joining Orexigen, Narachi served as chairman, chief executive and president of Ren Pharmaceuticals, a private biotech company, from November 2006 to March 2009, and chairman of the Board of directors of Naryx Pharma, a private pharma company.
In 2004, Narachi left Amgen where he served as an officer and vice president and, from 1999 through 2003, as general manager of Amgen’s Anemia Business. After joining Amgen in 1984, he held various positions throughout the organisation.
Narachi also currently serves as a member of the Board of directors of BIO, the Biotechnology Industry Organization, and AMAG Pharmaceuticals, a publicly traded pharmaceutical company.
Related Content
US pharma lobby launches legal action against the Trump administration over drug pricing proposals
US industry organisations including the Pharmaceutical Research and Manufacturers of America (PhRMA) have launched legal …
Pharma boosts lobby spending in first quarter of 2019
The Pharmaceutical Research and Manufacturers of America (PhRMA) trade lobbyists have spent near record levels …
New hospital-led organisation aims to tackle drug pricing problem by manufacturing generic drugs
Seven organisations representing around 500 US hospitals have become the governing members of a newly …
